Development of Radionuclides for Innovative Radiopharmaceuticals
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 256
Special Issue Editors
Interests: radionuclide production; radionuclide production targetry; radionuclide separations technology; nuclear physics; radioactive targets for nuclear physics applications
2. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
Interests: radionuclide development/production; chemical separation; ion exchange chromatography
Special Issue Information
Dear Colleagues,
Nuclear medicine is undergoing a renaissance built upon a renewed interest in theranostic pairs of radionuclides. The development of novel radionuclide production routes for innovative radiopharmaceutical manufacturing has pivoted from traditional one-source routes, i.e., cyclotron or reactor, to multi-route synchronized production methods utilizing all manner of particles in order to find matched pairs, and even triplets and quadruplets of radionuclides. The new radionuclide production environment brings together particle accelerators and reactors of all sizes in the search for the next golden bullet in the fight against human disease in general and cancer in particular. This Special Issue seeks to highlight the multitude of routes of producing radionuclides that are currently being utilized to usher in the next generation of innovative radiopharmaceuticals in order to lead the world in fighting disease.
Dr. Christiaan Etienne Vermeulen
Dr. Nicholas P. van der Meulen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radionuclide production: methods and technology
- radionuclide separations: methods and technology
- radionuclide production targetry
- novel radionuclide production routes
- innovative radiopharmaceuticals for targeted radionuclide therapy
